Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab
Allergy2021Vol. 76(9), pp. 2809–2826
Citations Over TimeTop 10% of 2021 papers
Monali Manohar, Diane Dunham, Sheena Gupta, Zheng Yan, Wenming Zhang, Samantha Minnicozzi, Matthew Kirkey, Bryan Bunning, Roshni Roy Chowdhury, Stephen J. Galli, Scott D. Boyd, Laurie Kost, R. Sharon Chinthrajah, Manisha Desai, Hans C. Oettgen, Holden T. Maecker, Wong Yu, Rosemarie H. DeKruyff, Sandra Andorf, Kari C. Nadeau
Abstract
This exploratory study provides novel comprehensive insight into the immune underpinnings of desensitization through omalizumab-facilitated mOIT. Moreover, this study provides encouraging results to support the complex immune changes that can be induced by OIT.
Related Papers
- → Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence(2021)136 cited
- → IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms(2022)51 cited
- → Development of a Monoclonal Anti-Immunoglobulin E Antibody (Omalizumab) for the Treatment of Allergic Respiratory Disorders(2001)145 cited
- → Development of Assay for Determining Free IgE Levels in Serum from Patients Treated with Omalizumab(2014)20 cited
- → Anti-immunoglobulin E (IgE) Therapy(2016)